Univariate analysis of the impact of clinical parameters and molecular alterations on OS in AML patients with intermediate-risk karyotype (N = 171)
| Variable . | OS, mo, median ± SD . | P . |
|---|---|---|
| Age, y | < .001 | |
| ≤ 60 | NR | |
| > 60 | 12.3 ± 4.6 | |
| WBC | .001 | |
| ≤ 50 000/μL | NR | |
| > 50 000/μL | 14.5 ± 3.6 | |
| NPM1+/FLT3-ITD− | .080 | |
| Yes | NR | |
| Others | 61.0 | |
| CEBPA | .010 | |
| Double mutation | NR | |
| Others | 22.0 ± 16.7 | |
| RUNX1 | .015 | |
| Mutated | 14.5 ± 3.8 | |
| Wild | NR | |
| TET2 | .021 | |
| Mutated | 14.7 ± 7.8 | |
| Wild | NR | |
| ASXL1 | .014 | |
| Mutated | 10.0 ± 3.2 | |
| Wild | NR |
| Variable . | OS, mo, median ± SD . | P . |
|---|---|---|
| Age, y | < .001 | |
| ≤ 60 | NR | |
| > 60 | 12.3 ± 4.6 | |
| WBC | .001 | |
| ≤ 50 000/μL | NR | |
| > 50 000/μL | 14.5 ± 3.6 | |
| NPM1+/FLT3-ITD− | .080 | |
| Yes | NR | |
| Others | 61.0 | |
| CEBPA | .010 | |
| Double mutation | NR | |
| Others | 22.0 ± 16.7 | |
| RUNX1 | .015 | |
| Mutated | 14.5 ± 3.8 | |
| Wild | NR | |
| TET2 | .021 | |
| Mutated | 14.7 ± 7.8 | |
| Wild | NR | |
| ASXL1 | .014 | |
| Mutated | 10.0 ± 3.2 | |
| Wild | NR |
Only variables with P < 0.1 are shown. KRAS, NRAS, WT1, MLL-PTD, FLT3-TKD, cKIT, and IDH1 mutations, and many other clinical parameters, such as hemoglobin, platelet counts, and sex, were not significantly associated with survival (P > 0.1) in this group of patients with intermediate-risk karyotype, and so were not listed in the table.